News
TLPH
1.044
+3.33%
0.034
Weekly Report: what happened at TLPH last week (0408-0412)?
Weekly Report · 3d ago
Weekly Report: what happened at TLPH last week (0401-0405)?
Weekly Report · 04/08 12:17
Weekly Report: what happened at TLPH last week (0325-0329)?
Weekly Report · 04/01 12:13
12 Health Care Stocks Moving In Thursday's After-Market Session
Qilian Intl Hldg Gr (NASDAQ:QLI) shares increased by 73.2% to $1.1 during Thursday's after-market session. Dare Bioscience stock rose 12.19% and Sunshine Biopharma stock increased by 37.85%. Vivos Therapeutics stock fell 12.6% as the company's Q4 earnings came out today.
Benzinga · 03/28 20:31
Weekly Report: what happened at TLPH last week (0318-0322)?
Weekly Report · 03/25 12:17
Weekly Report: what happened at TLPH last week (0311-0315)?
Weekly Report · 03/18 12:15
12 Health Care Stocks Moving In Monday's Pre-Market Session
TC BioPharm (Holdings) shares increased by 74.5% to $1.85 during Monday's pre-market session. Dyadic International stock rose 21.73% and Mesoblast shares rose 19.53%. Ainos (NASDAQ:AIMD) shares fell 15.6% and Nexalin Technology shares decreased by 11.64%.
Benzinga · 03/11 13:05
Weekly Report: what happened at TLPH last week (0304-0308)?
Weekly Report · 03/11 12:09
12 Health Care Stocks Moving In Friday's After-Market Session
Talphera (NASDAQ:TLPH) shares moved upwards by 15.6% to $1.3 during Friday's after-market session. The company's market cap stands at $3.4 billion. Genelux shares increased by 10.06% and Estrella Immunopharma stock rose 8.65%.
Benzinga · 03/08 21:31
Talphera, Inc. Is Worried About This – Should You Be Worried Too?
TipRanks · 03/08 06:00
12 Health Care Stocks Moving In Thursday's After-Market Session
Ainos (NASDAQ:AIMD) shares moved upwards by 100.0% to $2.24 during Thursday's after-market session. Unicycive Therapeutics stock rose 8.66% during the day. Talphera and Akili also moved upwards. Losers include Biofrontera and Creative Medical Tech.
Benzinga · 03/07 21:31
Talphera Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
Dow Jones · 03/07 12:23
HC Wainwright & Co. Reiterates Buy on Talphera, Maintains $6 Price Target
Benzinga · 03/07 12:12
Ed Arce Recommends ‘Buy’ on Talphera Amidst Promising Niyad Trial Progress and Strong Financial Positioning
TipRanks · 03/07 11:26
TLPH Stock Earnings: Talphera Misses EPS, Beats Revenue for Q4 2023
Talphera reported earnings per share of -25 cents. The company reported revenue of $281,000. This was 0.36% better than the analyst estimate of -20 cents. Talphera was down 7.7% in the after-hours trading session.
Investorplace · 03/07 02:53
AcelRx Pharmaceuticals GAAP EPS of -$0.25, revenue of $0.3M
Seeking Alpha · 03/06 21:33
Press Release: Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update
Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update. Company rebranding and corporate transformation to Talphera completed in Q1 2024. First patient enrollment in the NEPHRO CRRT registrational study expected in Q2 2024. Company expects a projected PMA submission to the FDA by the end of 2024.
Dow Jones · 03/06 21:05
Earnings Scheduled For March 6, 2024
Foot Locker is likely to report quarterly earnings at $0.32 per share on revenue of $2.28 billion. JD.com is expected to report earnings for its fourth quarter. CTS is estimated to report its quarterly earnings before the bell. Other companies reporting before the Bell include Campbell Soup, Super Group and Abercrombie & Fitch.
Benzinga · 03/06 10:00
Notable earnings after Wednesday's close
Seeking Alpha · 03/05 22:35
A Preview Of Talphera's Earnings
Talphera is set to give its latest quarterly earnings report on Wednesday, 2024-03-06. Analysts estimate the company will report an earnings per share of $-0.20. Last quarter the company beat EPS by $0.10. Shares of Talphera were trading at $1.3 as of March 04.
Benzinga · 03/05 19:02
More
Webull provides a variety of real-time TLPH stock news. You can receive the latest news about Talphera Inc through multiple platforms. This information may help you make smarter investment decisions.
About TLPH
Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is nafamostat formulation for direct intravenous (IV) infusion that shall be investigated and developed as a potential anti-viral for the treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. The Company is also engaged in developing two pre-filled syringes, namely Fedsyra and PFS-02.